ECO-PETROLEUM SOLUTIONS, INC.
CONSOLIDATED
BALANCE SHEETS
(Unaudited)

	September 30, 2017	December 31, 2016
ASSETS		
Current assets:		
Cash and cash equivalents	$ 100	$ -
A/R Related party - Patten Energy, Inc.	36,290	36,290
Allowance for bad debt	(36,290)	(36,290)
Total current assets	100	-
Property and equipment, net	59,888	55,292
Other assets:		
Goodwill	3,252,265	-
Total other assets	3,252,265	-
	$ 3,312,253	$ 55,292
LIABILITIES AND SHAREHOLDERS' DEFICIT		
Current liabilities:		
Accounts payable	$ 641,398	$ 215,227
Accrued expenses and other current liabilities	3,619,972	371,126
Short-term notes	360,306	297,706
Due to related parties:		
Promissory note - Former director and officer	35,000	35,000
Officers, Directors and stockholders	1,031,198	294,495
Current liabilities - Discontinued Operations	485,153	485,153
Total current liabilities	6,173,027	1,698,707
Total long term liabilities	840,500	-
Shareholders' Equity/(Deficit)		
Preferred stock, Series A $.0001 par value; 60,000,000 shares authorized, 60,000,000 and 0 issued and outstanding at September 30, 2017 and December 31, 2016, respectively	6,000	-
Preferred stock, Series B $.0001 par value; 465,000,000 shares authorized, 100,000,000 and 0 issued and outstanding at September 30, 2017 and December 31, 2016, respectively	10,000	-
Common stock, $.0001 par value; 600,000,000 shares authorized, 121,053,470 and 111,639,158 issued and outstanding at September 30, 2017 and December 31, 2016,	12,105	11,164
Common stock subscribed	57,496	-
Additional paid-in-capital	16,005,566	14,224,940
Accumulated Deficit	(19,792,442)	(15,879,519)
Total shareholders' equity/(deficit)	(3,701,274)	(1,643,415)
Total liabilities and shareholders' deficit	$ 3,312,253	$ 55,292

See accompanying notes to condensed consolidated financial statements.

ECO-PETROLEUM SOLUTIONS, INC.
CONSOLIDATED
STATEMENTS OF OPERATIONS
(Unaudited)

	For the Three Months Ended September 30, 2017	For the Three Months Ended September 30, 2016	For the Nine Months Ended September 30, 2017	For the Nine Months Ended September 30, 2016
Continuing Operations:				
Revenues	$ 190,000	$ -	$ 190,000	$ -
Cost of Goods Sold:				
Cost of Sales	129,000	-	129,000	-
Total expenses	129,000	-	129,000	-
Gross Profit	61,000	-	61,000	-
Expenses:				
General and administrative	$ 21,996	$ 2,250	$ 57,576	$ 43,040
Accrued salaries	72,301	-	216,904	-
Consulting	-	-	6,300	-
Professional fees	61,791	-	149,205	-
Depreciation and amortization	4,087	4,689	318,907	14,145
Total expenses	160,175	6,939	748,892	57,185
Loss from operations	(160,175)	(6,939)	(748,892)	(57,185)
Other income (expense):				
Interest expense	(13,395)	(5,479)	(45,338)	(16,437)
Forgiveness of Debt	-	-	820,457	-
Loss on disposal of subsidiary	-	-	-	(467,418)
Total other income (expense)	(13,395)	(5,479)	775,119	(483,855)
Income/(Loss) from continuing operations	(112,570)	(12,418)	87,227	(541,040)
Discontinued Operations:				
Income from operations of discontinued subsidiary	-	-	-	3,782
Income from Discontinued Operations	-	-	-	3,782
Net income/(loss)	$ (112,570)	$ (12,418)	$ 87,227	$ (537,258)
Basic and diluted loss per common share				
Loss from Continuing Operations	$ (0.00)	$ (0.00)	$ 0.00	$ (0.00)
Income from Discontinued Operations	$ -	$ -	$ -	$ 0.00
Weighted average shares outstanding - Basic and Dilu	118,311,940	110,793,553	116,122,164	110,793,553

See accompanying notes to condensed consolidated financial statements.

Eco-Petroleum Solutions, Inc.
Consolidated
Statement of Stockholder's Equity (Deficit)
For the Period from December 31, 2015 to September 30, 2017
(Unaudited)

	Preferred Stock Series A	Preferred Stock Series A Amount	Preferred Stock Series B	Preferred Stock Series B Amount	Common Stock	Common Stock Amount	Additional Paid-in Capital	Common Stock Subscribed	Earnings (Deficit) Accumulated	Total
Balance, December 31, 2015	**-**	**$ -**	**-**	**$ -**	**115,639,158**	**$ 11,564**	**$ 14,248,540**	**-**	**$ (15,329,927)**	**$ (1,069,823)**
Common stock returned for subsidiary	-	-	-	-	(4,000,000)	(400)	(23,600)			(24,000)
Net loss, December 31, 2016									(549,592)	(549,592)
Balance, December 31, 2016	**-**	**$ -**	**-**	**$ -**	**111,639,158**	**$ 11,164**	**$ 14,224,940**	**-**	**$ (15,879,519)**	**$ (1,643,415)**
Net loss, March 31, 2017									(70,356)	(70,356)
Balance, March 31, 2017	**-**	**$ -**	**-**	**$ -**	**111,639,158**	**$ 11,164**	**$ 14,224,940**	**-**	**$ (15,949,875)**	**$ (1,713,771)**
Stock issued for purchase of subsidiary	60,000,000	6,000	100,000,000	10,000	-	-	1,763,916	57,496	(4,000,150)	(2,162,738)
Stock issued for conversion of debt	-	-	-	-	9,414,312	941	16,710	-	-	17,652
Net income, June 30, 2017								-	270,153	270,153
Balance, June 30, 2017	**60,000,000**	**$ 6,000**	**100,000,000**	**$ 10,000**	**121,053,470**	**$ 12,105**	**$ 16,005,566**	**57,496**	**$ (19,679,872)**	**$ (3,588,704)**
Net income, September 30, 2017								-	(112,570)	(112,570)
Balance, September 30, 2017	**60,000,000**	**$ 6,000**	**100,000,000**	**$ 10,000**	**121,053,470**	**$ 12,105**	**$ 16,005,566**	**57,496**	**$ (19,792,442)**	**$ (3,701,274)**

See accompanying notes to condensed consolidated financial statements

ECO-PETROLEUM SOLUTIONS, INC.
Consolidated
Statements of Cash Flows
(Unaudited)

	For the Nine Months Ended September 30, 2017	For the Nine Months Ended September 30, 2016
Cash flows from operating activities		
Net loss	$ 87,227	$ (537,258)
Adjustments to reconcile net loss to net cash provided by operating activities:		
Non-cash expenses:		
Depreciation and amortization	318,907	14,145
Bad debt	820,457	36,290
Changes in operating assets and liabilities:		
(Increase) decrease in accounts receivable	-	5,850
(Increase) decrease in inventory	-	62,215
Increase (decrease) in accounts payable	426,171	(24,152)
Increase (decrease) in accrued expenses and other current liabilities	3,248,846	(8,616)
Net cash provided by operating activities	4,901,608	(451,526)
Cash flows from investing activities		
Investment in equipment	(18,496)	-
Return on investment of sale of subsidiary	-	451,076
Investment of subsidiary	(4,940,885)	-
Net cash used by investing activities	(4,959,381)	451,076
Cash flows from financing activities		
Payments on notes payable	(54,310)	(4,500)
Proceeds on notes payable	76,300	-
Return of common stock for disposal of subsidiary	-	(24,000)
Proceeds on loans from related parties - Directors and stockholders	35,883	17,250
Net cash provided by financing activities	57,873	(11,250)
Increase in cash	100	(11,700)
Cash at beginning of period	-	11,700
Cash at end of period	$ 100	$ -
Supplemental Cash Flow Information:		
Cash paid for interest	$ -	$ -
Cash paid for income taxes	$ -	$ -

See accompanying notes to condensed consolidated financial statements.

(1) Basis of Presentation and Organization

Eco-Petroleum Solutions, Inc. ("Eco-Petroleum" or the "Company") is a Delaware corporation. On November 25, 2004, the Company changed its name to Falcon Media Services, Ltd. On November 12, 2008, the Company changed its name to Extreme Mobile Coatings Corp., Ltd. On March 2, 2009, the Company changed its name to Extreme Mobile Coatings Worldwide Corp. On May 19, 2010, the Company changed its name to Structural Enhancement Technologies Corp. ("Structural"). On November 16, 2012, the Company changed its name to Eco-Petroleum Solutions, Inc.

On March 11, 2016 the Company cancelled its January 7, 2015 agreement with Bottled Brands Acquisition Corp (originally purchased for 8,000,000 shares) for the return of 4,000,000 shares of the Company's common stock.

On March 9, 2017, the Company entered into an agreement with the shareholders of Immunotech Laboratories, Inc. (Immunotech) to acquire all of the outstanding shares, both preferred and common stock, of Immunotech for 60,000,000 shares of the Company's Series A preferred stock and 391,578,947 shares of the Company's Series B preferred stock. The current shareholders of Immunotech's ownership of the Company will not be less than the equivalent of 80% of the issued and outstanding shares of ECPO common stock at any given time. At the effective time of the Acquisition, all options to acquire common stock of Immunotech issued and outstanding, whether vested or unvested, shall automatically be converted into and become options to purchase shares of Common Stock. Immunotech's 200 Million outstanding Series B Preferred convert one for two but do have a voting preference and shall be exchanged for 100 Million Series B Preferred shares of ECPO with the exact same voting preferences as the Immunotech Series B Preferred. The Series B outstanding will be included in the 80% calculation for the Newly Created Preferred. The Company will issue 291,578,947 series B preferred in exchange of 574,964,967 of common stock of Immunotech. As part of the share exchange agreement, all the liabilities of Immunotech Laboratories, Inc. were assumed by Eco-Petroleum Solutions, Inc.

Immunotech Laboratories, Inc. is a wholly-owned subsidiary of Eco-Petroleum, Inc. (as of March 9th, 2017) incorporated in the State of Nevada on April 11, 2000 under the name of "Earthnet Media.com". On November 2, 2006, changed its name to "International Technology Systems, inc. and then on December 18, 2008 changed its name to Immunotech Laboratories, Inc. trading under the symbol IMMB. The Company focuses on Research and Development in the Bio-Tech Field as a drug development company committed to the commercialization of its proprietary proteins known as IRREVERSIBLE PEPSIN FRACTION (IPF) ITV-1 for the treatment of debilitating infectious disease such as HIV and Hepatitis Type C. These drugs have not been approved by the FDA but the Company has begun pre-clinical trial testing. The Company has also began the final phase of clinical trials during the period ended March 31, 2016 in Bulgaria through a minority owned entity, Immunotech Laboratories, BG ("ILBG") which IMMB owns 49%. The Clinical Trials were successfully completed Bulgaria in the fourth quarter of 2016. In pursuit of this strategy, on December, 2009 we entered into a Licensing Agreement (the "Agreement"), with the Zhabilov Trust, a California Trust ("Z Trust" or the "Seller") and the Trustees of the Z Trust ("Trustees"). Pursuant to the terms of the Agreement, we agreed to pay $1,550,000.00 Licensing fee to the Trust for exclusive rights to the Patent for proteins to be used to develop a drug treatment for HIV. The exclusivity is for a period of 20 years with approximately 12 years remaining.

On June 22, 2017, Eco Petroleum Solutions, Inc. (OTC Markets "ECPO" or the "Company") announces that IMMB BG a subsidiary of Immunotech Laboratories, Inc., the Company's subsidiary, has issued an exclusive Distribution Agreement (the "Agreement") for the territory of the Ukraine to LLC Project Development and Implementation Centre Omega ("Omega"). The term of the agreement is for an initial ten-year period with an option to renew the agreement for an additional ten years. The Agreement establishes a price of €3,300 (Euros) per one 8-week cycle of injections or 16 vials. The treatment protocol requires two 8 week cycles of injections administered twice a week with a one week break between cycles. The ITV-1 treatment will be administered with a combination of different variations of Protease Inhibitors used in the treatment of HIV/AIDS.

Financial Statements
The accompanying financial statements of Eco-Petroleum for SEPTEMBER 30, 2017 and December 31, 2016, have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). The accompanying financial statements have not been audited or reviewed. The financial statements are presented as consolidated for the quarter June 30, 2017.

In the opinion of management, the financial statements include all known adjustments (which consist primarily of normal, recurring accruals, estimates, and assumptions that impact the financial statements) necessary to present fairly the financial position as of the balance sheet dates and the results of operations for the years then ended, and cumulative from inception.

Cash and Cash Equivalents
For the Statements of Cash Flows, all highly liquid investments with maturity of three months or less are considered to be cash equivalents.

Property and Equipment
Property and equipment are recorded at historical cost. Major additions and renewals are capitalized and depreciated over their estimated useful lives. The Company uses the straight-line method of depreciation. The estimated useful lives for significant property and equipment categories are as follows:

Office and computer equipment	3-7 years
Machinery and equipment	5-10 years

Impairment of Long-Lived Assets
The Company evaluates the recoverability of long-lived assets and the related estimated remaining lives at each balance sheet date. The Company records an impairment or change in useful life whenever events or changes in circumstances indicate that the carrying amount may not be recoverable or the useful life has changed. During the periods ended September 30,2017 and December 31, 2016, the assets of Eco-Petroleum were fully depreciated as no longer using the assets for that division of business when the Company decided to acquire Immunotech and no events or circumstances occurred for which an evaluation of the recoverability of long-lived assets was required in 2016.

Loss per Common Share
Basic net loss per share is calculated based on the weighted-average number of common shares outstanding. Diluted net loss per share is calculated using the weighted-average number of common shares outstanding plus common stock equivalents. Common stock equivalents are excluded from the calculation of diluted net loss per share when their effect is anti-dilutive.

Stock-Based Compensation Arrangements
The Company accounts for stock-based compensation arrangements in accordance with guidance provided by the Financial Accounting Standards Board Accounting Standards Codification ("ASC"). This guidance addresses all forms of share-based payment awards including shares issued under employee stock purchase plans, stock options, restricted stock and stock appreciation rights, as well as share grants and other awards issued to employees and non-employees under free-standing arrangements. These awards are recorded at costs that are measured at fair value on the awards' grant dates, based on the estimated number of awards that are expected to vest and will result in charges to operations.

From time to time, the Company's shares of common stock have been issued as payment to employees and non-employees for services and the reduction of debt. These are non-cash transactions that require management to make judgments related to the fair value of the shares issued, which affects the amounts reported in the Company's accompanying financial statements for certain of its assets and expenses.

Income Taxes
The Company account for income taxes pursuant to ASC Topic 740, "*Income Taxes*". Under ASC Topic 740, deferred tax assets and liabilities are determined based on temporary differences between the bases of certain assets and liabilities for income tax and financial reporting purposes. The deferred tax assets and liabilities are classified according to the financial statement classification of the assets and liabilities generating the differences.

Deferred Offering Costs
The Company defers as other assets the direct incremental costs of raising capital until such time as the offering is completed. At the time of the completion of the offering, the costs are charged against the capital raised. Should the offering be terminated, deferred offering costs are charged to operations during the period in which the offering is terminated.

Reclassification
Certain items have been reclassified in 2016 in order to be compatible with corresponding amounts in the financial statement presentation in 2017.

Recent Accounting Pronouncements
The management of the Company does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the accompanying financial statements.

(2) Going Concern

Management of the Company believes that the Company will be successful in its capital formation and operating activities, there can be no assurance that it will be able to raise additional equity capital, or be able to generate sufficient revenues to sustain its operations. The Company also intends to conduct additional capital formation activities through the issuance of its common stock to establish sufficient working capital, and, expand its operations.

The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (GAAP), which contemplate continuation of the Company as a going concern.

The Company has incurred an operating loss since inception and the cash resources of the Company are insufficient to meet its planned business objectives. These and other factors raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

(3) Related Party Transactions

As of September 30, 2017 and December 31, 2016, the Company owed to Directors, officers and stockholders of the Company $1,031,198 and $294,495 respectively. The amounts are unsecured, non-interest bearing, and have no terms for repayment. The individual amounts owed to Directors, officers and stockholders are presented as follows:

	As of	
	September 30, 2017	**December 31, 2016**
James W. Zimbler	$ 140,571	$ 125,147
Union Square Energy Advisors	169,348	169,348
Harry Zhabilov	721,279	0
Totals	$ 1,031,198	$ 294,495

On May 20, 2010, a Director and former officer of the Company loaned $35,000, and received a promissory note from the Company with an annual interest rate of 8%. The note has a term of six months, at which time, the principal and accrued interest are due and payable. The note can be prepaid at any time and from time to time at par and accrued interest. The principal and interest of the note are also convertible to 20,000 shares of the Company's common stock (post reverse stock split) at the end of the six-month term at the designation of the holder. As of September 30, 2017, and December 31, 2016, the promissory note was in default, and the amount of $35,000 of principal on the note was due and payable to the note holder plus accrued interest of $19,907, and $18,507, respectively. Interest expense related to this loan was $1,400 and $2,800 for the six months ended September 30,2017 and December 31, 2016, respectively.

(3) Related Party Transactions (cont.)

The Company entered into an evergreen employment contract with Harry Zhabilov, Chief Executive Officer, Chairman and majority voting shareholder on January 1, 2012. No payment has been made under this contract, but the salary has accrued from inception to the current reporting period. An accrued balance from the previous employment agreement of $177,130 is also outstanding and included in the $1,478,522 salary reported in the accrued expense and other accrual balance.

(4) Income Taxes

The provision (benefit) for income taxes for the years ended September 30,2017 and December 31, 2016, were as follows (assuming a 40 percent effective tax rate):

	For the Years Ended	
	September 30, 2017	**December 31, 2016**
Federal and state-		
Taxable income	$ -	$ -
Total current tax provisions	$ -	$ -
Federal and state-		
Loss carryforwards	$ 0	$ 219,837
Change in valuation allowance	(0)	(219,837)
Total deferred tax provision	$ -	$ -

The Company had deferred income tax asset as follows:

	As of	
	September 30, 2017	**December 31, 2016**
Loss carryforwards	$ 4,186,682	$ 4,221,572
Less-Valuation allowance	$ (4,186,682)	$ (4,221,572)
Total net deferred assets	$ -	$ -

The Company has provided a valuation allowance equal to the deferred income tax assets for the years ended September 30,2017 and December 31, 2016, respectively, because it is not presently known whether future taxable income will be sufficient to utilize the loss carryforwards.

In tax loss carryforwards that can, upon filing of the appropriate tax returns, be utilized in future periods to reduce taxable income, which expire in 2028 through 3036.

The management of the Company has not filed federal or state income tax returns for the years 2008 – 2016 with the respective tax authorities.

(5) Notes Payable and Long-term Debt

Notes payable and long-term debt as of September 30,2017 and December 31, 2016, consisted of the following:

Short-term notes payable as of September 30,2017 and December 31, 2016, consisted, in part, of two separate notes given to the same holder, one for $100,000, dated November 3, 2009, and the other for $50,000, dated January 11, 2010. Both notes had six-month terms and accrued interest at 8 percent per annum. As of September 30, 2017 and December 31, 2016, both notes were in default and, as such, the holder has the right to convert the amounts to shares of restricted common stock at a 25 percent discount to the thirty-day average closing price prior to the date of conversion. Subsequent to December 31, 2010, the holder agreed not to convert the debt to shares and to settle these obligations for $150,000, plus accrued interest, in connection with the completion of a merger transaction with Landmark Consulting, Inc. The transaction with Landmark was not completed by the Company. Subsequently, on February 14, 2012, the Company issued 50,000 shares of registered common stock to the holder (post reverse stock split) in satisfaction of $50,000 in principal on the notes. In addition, on October 29, 2013, the Company issued 1,500,000 shares of restricted common stock in satisfaction of $30,206 of accrued interest, and $29,794 of principal on the notes, and paid an additional $10,000 of accrued interest in cash. On May, 25, 2017, the Company issued 9,414,312 shares of restricted common stock in satisfaction of $11,000 in principal on the notes and $6,651.84 of accrued interest. The balance remaining is $59,206.

On November 21, 2011 Immunotech Laboratories, Inc. issued a non-interest bearing irrevocable promissory note, due November 20, 2012 to Dr. Ara Yaghijan in the amount of $200,000.00 payable in cash. In September of 2014 the note was purchased by Harry Zhabilov, CEO of Immunotech Laboratories, Inc.

On November 21, 2011 Immunotech Laboratories, Inc. issued a demand promissory note bearing interest at the rate of 9.076% in the amount of $250,000.00 to Harry Zhabilov, CEO of Immunotech Laboratories, Inc. for accrued payroll

On April 13, 2012, the Company issued a promissory note, due October 31, 2012, to a stockholder for $15,000. The note carries an interest rate of 10 percent per annum, and may be either repaid, at the election of the note holder in cash plus the issuance of shares of common stock of the Company in the amount of $30,000 in value, or by the conversion of the principal and interest due into a total of $45,000 in value of common stock of the Company, along with additional warrants to purchase common stock of the Company with an additional value of $10,000, with such warrants being exercisable within one year from the date of issuance, and shall have an exercise price equal to 50 percent of the average closing price of the common stock of the Company on the five trading days prior to exercise. As of December 31, 2016 and 2015, the promissory note was in default. The promissory note is guaranteed by shares of common stock of the Company owned by James W. Zimbler, a Director and stockholder of the Company.

On September 25, 2013, the Company issued a promissory note, due December 24, 2013, to an unrelated entity for $50,000 in proceeds. The note carries an interest rate of 10 percent per annum, and may be repaid with appropriate interest to the note holder by the Company on the earlier of the due date or the date the Company raises in excess of $500,000 from its current capital formation activities, or all or a portion of the principal and accrued and unpaid interest may be converted, at the election of the note holder, into shares of common stock of the Company at a price equal to 85 percent of the market price (meaning the average of the lowest two trading prices for the five-day trading period before the date of conversion) of the Company's common stock. As of December 31, 2016 and December 31, 2015, the promissory note was in default, and the Company obtained a written waiver from the note

holder dated March 26, 2014, and a subsequent verbal waiver, confirming that all terms and conditions contained in the promissory note would remain in effect as the Company was continuing with its capital formation activities. Further, on February 11, 2014, the Company issued 100,000 shares of common stock to the note holder, with a value of $5,000, as an incentive to continue working with the Company on its capital formation and other merger activities.

On October 18, 2013, the Company issued a second promissory note, due January 16, 2014, to the same note holder as the September 25, 2013 promissory note, for $100,000 in proceeds. The note carries an interest rate of 10 percent per annum, and may be repaid with appropriate interest to the note holder by the Company on the earlier of the due date or the date the Company raises in excess of $750,000 from its current capital formation activities, or all or a portion of the principal and accrued and unpaid interest may be converted, at the election of the note holder, into shares of common stock of the Company at a price equal to 85 percent of the market price (meaning the average of the lowest two trading prices for the five-day trading period before the date of conversion) of the Company's common stock. As of December 31, 2016 and December 31, 2015, the promissory note was in default, and the Company obtained a written waiver from the note holder dated March 26, 2014, and a subsequent verbal waiver, confirming that all terms and conditions contained in the promissory note would remain in effect as the Company was continuing with its capital formation and other merger activities. Further, on February 11, 2014, as a condition of the promissory note, the Company issued 200,000 shares of common stock to the note holder, with a value of $10,000, as an incentive to make the loan.

On September 21, 2012, the Company entered into a Settlement Agreement with Mr. Peter Mergenthaler, individually and as the agent for Eastern Glow Investments, Ltd. and Kingsgate Development, Ltd., entities who were initial stockholders of the Company when it was known as Falcon Media Services, Ltd., James W. Zimbler, Challenger Brands Corp., and the Company.
A debt purchase agreement was entered in on January 29, 2015. On February 10, 2015, the Company issued a total of 10,000,000 shares to Mr. Mergenthaler in settlement of $190,000 of the amount due him, reducing the total amount owed of the note payable from $283,500 to the amount of $71,500. On September 30,2017 and December 31, 2016, the Company owed $59,800 and $62,500, respectively.

On February 27, 2017, the Company issued a promissory note to an unrelated party, due March 27, 2017, for $10,800 in proceeds. The note carries an interest rate of 12 percent per annum.

On March 9, 2017, the Company issued a promissory note to an unrelated party, due March 9, 2018, for $25,000 in proceeds. The note carries an interest rate of 12 percent per annum, compounded, and may be either repaid, at the election of the note holder in cash or the issuance of shares of common stock of the Company at a discount to market equal to 50% discount to the lowest closing bid during the past 10 days. The Holder's right to convert the note will be triggered upon the occurrence of one of the following: (i) 6 months from the date of said note, (ii) changed in control of the Company, (iii) the filing of a registration statement or offering, or (iv) election by the holder.

On May 23, 2017, the Company issued a promissory note to an unrelated party, due May 22, 2018, for $6,500 in proceeds. The note carries an interest rate of 12 percent per annum, compounded, and may be either repaid, at the election of the note holder in cash or the issuance of shares of common stock of the Company at a discount to market equal to 50% discount to the lowest closing bid during the past 10 days. The Holder's right to convert the note will be triggered upon the occurrence of one of the following: (i) 6 months from the date of said note, (ii) changed in control of the Company, (iii) the filing of a registration statement or offering, or (iv) election by the holder.

On May 26, 2017, the Company issued a promissory note to an unrelated party, due June 23, 2018, for $5,000 in proceeds. The note carries an interest rate of 12 percent per annum, compounded, and may be either repaid, at the election of the note holder in cash or the issuance of shares of common stock of the Company at a discount to market equal to 50% discount to the lowest closing bid during the past 10 days. The Holder's right to convert the note will be triggered upon the occurrence of one of the following: (i) 6 months from the date of said note, (ii) changed in control of the Company, (iii) the filing of a registration statement or offering, or (iv) election by the holder.

On June 20, 2017, the Company issued a promissory note to an unrelated party, due June 19, 2018, for $3,000 in proceeds. The note carries an interest rate of 12 percent per annum, compounded, and may be either repaid, at the election of the note holder in cash or the issuance of shares of common stock of the Company at a discount to market equal to 50% discount to the lowest closing bid during the past 10 days. The Holder's right to convert the note will be triggered upon the occurrence of one of the following: (i) 6 months from the date of said note, (ii) changed in control of the Company, (iii) the filing of a registration statement or offering, or (iv) election by the holder.

On June 22, 2017, the Company issued a promissory note to an unrelated party, due June 23, 2018, for $1,000 in proceeds. The note carries an interest rate of 12 percent per annum, compounded, and may be either repaid, at the election of the note holder in cash or the issuance of shares of common stock of the Company at a discount to market equal to 50% discount to the lowest closing bid during the past 10 days. The Holder's right to convert the note will be triggered upon the occurrence of one of the following: (i) 6 months from the date of said note, (ii) changed in control of the Company, (iii) the filing of a registration statement or offering, or (iv) election by the holder.

On July 10, 2017, Immunotech Laboratories, Inc. issued an 8% Convertible Promissory Note due July 10, 2018 for $10,000 in proceeds. The holder of this note may elect to convert this note, all or part of the principal and interest balance, into shares of common stock of Immunotech Laboratories, Inc., a subsidiary of the Company, at a 50% discount to the lowest closing bid price over the past 10 trading days not to exceed 9.9% of the outstanding stock of Immunotech Laboratories, Inc. at any time.

Included below is a summary of the Company's notes payable:

	As of September 30, 2017	As of December 31, 2016
Convertible promissory notes, due on April 28, 2010, interest at 8.0% per annum, unsecured	$ 59,706	$ 70,206
Promissory note, due on November 21, 2011, no interest, unsecured	200,000	-
Demand promissory note, interest at 9.067% per annum, unsecured	250,000	-
Convertible promissory notes, due on December 24, 2013, interest at 10.0% per annum, unsecured	50,000	50,000
Convertible promissory notes, due on January 16, 2014, interest at 10.0% per annum, unsecured	100,000	100,000
Convertible promissory notes, due on October 31, 2012, interest at 10.0% per annum, unsecured	15,000	15,000
Promissory note, no interest, unsecured	59,800	62,500
Convertible promissory notes, due on March 9, 2018, interest at 12.0% per annum, unsecured	25,000	-
Convertible promissory notes, due on March 27, 2018, interest at 12.0% per annum, unsecured	10,800	-
Convertible promissory notes, due on May 22, 2018, interest at 12.0% per annum, unsecured	6,500	-
Convertible promissory notes, due on June 23, 2018, interest at 12.0% per annum, unsecured	5,000	-
Convertible promissory notes, due on June 19, 2018, interest at 12.0% per annum, unsecured	3,000	-
Convertible promissory notes, due on June 23, 2018, interest at 12.0% per annum, unsecured	1,000	-
Convertible promissory notes, due on September 14, 2018, interest at 12.0% per annum, unsecured	25,000	-
	$ 810,806	$ 297,706
Less: Short Term payables	(810,806)	(297,706)
Long term note payables	$ -	$ -

(6) Discontinued Operations

Effective September 30, 2014, the Board of Directors of the Company resolved to discontinue the operations of EMC, its wholly owned subsidiary. As such, the assets and accumulated depreciation of EMC's property and equipment were removed from the accounts, and all remaining liabilities were classified as Discontinued Operations in the accompanying Balance Sheets. As of September 30, 2017 and December 31, 2016, the summaries of liabilities pertaining to discontinued operations were as follows:

	As of	
	September 30, 2017	**December 31, 2016**
Bank loan, monthly payments of $2,736 through 2015, interest at 8.5% per annum, secured	$ 33,359	$ 33,359
Accounts payable - Trade	6,000	6,000
Accrued liabilities	36,800	36,800
Payroll and sales taxes payable	8,200	8,200
Due to related party - Stockholder	400,794	400,794
Totals	$ 485,153	$ 485,153

The impacts of the discontinued operations of EMC are also disclosed in the accompanying Statements of Operations.

SABA Asset Purchase

As of September 30, 2017 and December 31, 2016, EMC owed $33,359, and $33,359, respectively, on the loan from Central Bank FSG related to the SABA Asset Purchase Agreement dated March 5, 2007. EMC has not been able to obtain clear title of the construction equipment for the purpose of selling the equipment to recover funds to repay the bank loan.

(7) Common Stock

On March 11, 2016, the Company's subsidiary Bottled Brands returned 4,000,000 shares of the Company's common stock for the cancellation of the agreement of Bottled Brands LLC.

On March 9, 2017, The Company changed the authorized shares of stock to 60,000,000 shares of Series A Preferred, 465,000,000 shares of Series B Preferred Stock and 600,000,000 shares of common stock.

As of September 30, 2017 and December 31, 2016, 121,053,470 and 111,639,158 shares, respectively, of the registrant's common stock, par value of $0.0001, were issued and outstanding.

(8) Preferred Stock

On March 9, 2017, the Company created two new classes of Preferred Stock, 60,000,000 shares of Series A, authorized, and 465,000,000 shares of Series B, authorized.

As of September 30, 2017 and December 31, 2016, 60,000,000 and 0 shares, respectively, of the registrant's preferred stock-Series A, par value of $0.0001, were issued and outstanding and 100,000,000 and 0 shares, respectively, of the registrant's preferred stock-Series B, par value of $0.0001, were issued and outstanding.

(9) Subsequent Events

On October 29, 2017, The Company filed with FINRA a Notice of share exchange for its subsidiary Immunotech Laboratories, Inc. The Company's filing for ECPO with FINRA is still under review as a result of FINRA's request for the filing by Immunotech Laboratories, Inc.

On October 1st, 2017 the company amended the consulting Agreement entered in June of 2014 into between Immunotech Laboratories, Inc and Camelot Financial Group, LLC. The original agreement was for accounting and business development services with the amount invoiced being payable in cash or shares at the election of the Company when paid. The original conversion feature was set at a Fifty Percent (50%) discount to the lowest bid price in the proceeding 30 days of the original invoice of Immunotech Laboratories, Inc. The Company has negotiated a fixed price of $.004 with a reset upon the issuance of any convertible instrument with a lower conversion price. The first payment due under the amended contract is upon the shipping of the first order. There is a default provision for non-payment and a cure period. Payment in stock or cash at the Company's election applies. The balance accrued under this contract included in the accounts payable balance is $412,500.00 at September 30, 2017. This payable along with all the other liabilities of Immunotech Laboratories, Inc were assumed by the Company on March 9, 2017 as part of the Share Exchange Agreement.

The validation protocol for the initial order of 7,000 vials has been completed and the documentation is currently being edited by the company for submission to the appropriate Bulgarian regulatory agencies.

On October 25, 2017, the Company's subsidiary Immunotech Laboratories, Inc. submitted a request to for the retirement of the Immunotech Laboratories, Inc. symbol from the OTC Market. The Company has received comments and responded and expects the process to be completed within the 90-day time frame.